Your concern as an ARIA investor is not whether Tasigna, specifically, can cure CML for a significant proportion of patients, but rather is whether any drug (including Ponatinib) can. If CML were to become a non-chronic disease for a significant proportion of patients, the valuation arithmetic on ARIA would have to be adjusted rather drastically.
News 
Market Data 
Discover 
